Converting cancer mutations into therapeutic opportunities

EMBO Molecular Medicine

Volumn 1, Issue 6-7, 2009, Pages 297-299

  O'Brien, Tom ^a   Stokoe, David ^a  

^a GENENTECH INC   (United States)

Author keywords

Cancer; Methotrexate; MSH2; Olaparib; PTEN

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; 8 HYDROXYDEOXYGUANOSINE; BCR ABL PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; BSI 201; CYCLIN DEPENDENT KINASE 6; DIHYDROFOLATE REDUCTASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA PROTEIN; IMATINIB; IRINOTECAN; METHOTREXATE; MICROSPHERULE PROTEIN 58; MK 4827; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PHOSPHATE; PHOSPHATIDYL INOSITOL 3,4,5 TRIS PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN MSH2; PROTEIN P53; RAD51 PROTEIN; SMALL INTERFERING RNA; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLELE; ANEUPLOIDY; BREAST CANCER; CANCER CELL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME; CHROMOSOME 10; CHROMOSOME 2; CHROMOSOME DELETION; CLINICAL TRIAL; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG DOSE INCREASE; EXCISION REPAIR; GENE MUTATION; HUMAN; LETHALITY; MISMATCH REPAIR; OVARY CANCER; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; SYNTHETIC LETHALITY; TARGET CELL; TUMOR GENE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METHOTREXATE; MUTATION; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS; PHTHALAZINES; PIPERAZINES; POLY(ADP-RIBOSE) POLYMERASES; PTEN PHOSPHOHYDROLASE;

EID: 77953653251     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.200900044     Document Type: Short Survey

References (11)

1. Bommi-Reddy A, Almeciga I, Sawyer J, Geisen C, Li W, Harlow E, Kaelin WG, Jr., Grueneberg DA (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen. Proc Natl Acad Sci USA 105: 16484-16489
2. HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T (2005) Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917
3. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al(2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921
4. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ,et al(2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134
5. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375-13378
6. Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ (2009) Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. Embo Mol Med 1: 323-337
7. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Waldman T, Lord CJ, Ashworth A (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. Embo Mol Med 1: 315-322
8. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O'Connor MJ, Tutt AN, Zdzienicka MZ, et al(2006) Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115
9. Puc J, Keniry M, Li HS, Pandita TK, Choudhury AD, Memeo L, Mansukhani M, Murty VV, Gaciong Z, Meek SE,et al.(2005) Lack of PTEN sequesters CHK1 and initiates genetic instability. Cancer Cell 7: 193-204
10. Sawyers CL (2009) Finding and drugging the vulnerabilities of RAS-dependent cancers Cancer Cell 137: 796-798
11. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170